Immune-Based Lymphoma Treatment Sho... (ype of cancer said Dr. Sonali Smith an ...)

Immune-Based Lymphoma Treatment Shows Promise

Date:5/31/2009

ype of cancer," said Dr. Sonali Smith, an associate professor of medicine at the University of Chicago Medical Center, who moderated the press briefing. "I would consider this extremely promising, and repeating this study is not helpful to patients.

And in yet another example of more targeted, personalized cancer care, scientists in France reported on a possible biomarker -- a protein known as MSH2 -- that might predict which patients with non-small cell lung cancer will fare better on cisplatin-based chemotherapy.

MSH2 is one of a family of DNA repair genes, the irony being that the gene also repairs DNA purposely damaged by chemotherapy. Not surprisingly, then, patients with either low levels of MSH2 or none at all respond better to cisplatin treatment than patients with higher levels.

"The findings duplicate those of a prior study that showed similar results with a different DNA repair gene, ERCC1," noted Dr. George Simon, director of the thoracic oncology program at Fox Chase Cancer Center in Philadelphia. "When these two genes are taken in combination, they seem to predict better than ERCC1 alone."

More information

Find out more about more targeted cancer care at the Personalized Medicine Coalition.

SOURCES: Louis M. Weiner, M.D., director, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C.; George Simon, M.D., director, thoracic oncology program, Fox Chase Cancer Center, Philadelphia; Margaret von Mehren, M.D., medical oncologist, Fox Chase Cancer Center, Philadelphia; May 31, 2009, news conference with Sonali Smith, M.D., associate professor, medicine, University of Chicago Medical Center; Stephen J. Schuster, M.D., associate professor, University of Pennsylvania School of Medicine, Philadelphia; Eric Van Cutsem, M.D., Ph.D., professor, University Hospital Gas
'/>"/>

1

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Immune-based drug approved in Europe for pediatric cancer patients
2. The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia
3. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
4. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
5. January 1 Looms Large for Lymphoma Patients
6. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
7. Possible Cure for Rare Lymphoma Reported
8. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
9. Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma
10. Genmab Initiates Ofatumumab Phase II Study in Diffuse Large B-Cell Lymphoma
11. Lymphoma drug used to treat skin disorders

Post Your Comments:

Immune-Based Lymphoma Treatment Sho...(ype of cancer said Dr. Sonali Smith an ...),Health